PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Paused · Phase 1/Phase 2
Conditions studied: Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
In brief
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
Key facts
- Study ID
- NCT06639607
- Run by
- Washington University School of Medicine
- People needed
- 68
- Starts
- 2026-08-31
- Expected to finish
- 2051-06-30
- Last updated by the study team
- 2026-07-20
Who can join
Age: 4 and older, up to 25. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Washington University School of Medicine — St Louis, Missouri, United States
- Duke University Medical Center — Durham, North Carolina, United States
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.